Evofem Biosciences' GAAP loss for 2021 was $205.192 million, up 44.2% from $142.309 million in the previous year. Revenue increased 18.5 times to $8.244 million from $0.446 million a year earlier.
Evofem Biosciences' GAAP loss for 2021 was $205.192 million, up 44.2% from $142.309 million in the previous year. Revenue increased 18.5 times to $8.244 million from $0.446 million a year earlier. 
evofem.investorroom.com
English (US) 